Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Urotronic

Urotronic
2015 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$26.1M LATEST DEAL AMOUNT
5 INVESTORS
Description

Developer of drug-coated balloon devices intended to provide a low cost, minimally-invasive treatment option for men suffering from urinary tract conditions. The company's drug-coated balloon devices combines balloon dilation and drug delivery to uptake highly lipophilic drug, paclitaxel, limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence and it localizes drug delivery through micro tissue separations created by balloon expansion, ensures that circumferential drug effectively covers the stricture, enabling doctors to treat diseases related to urology.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Drug Delivery
Other Devices and Supplies
Primary Office
  • 2495 Xenium Lane North
  • Plymouth, MN 55441
  • United States

+1 (763) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Urotronic’s full profile, request a free trial.

Urotronic Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 21-Aug-2018 $26.1M 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A3) 08-Sep-2016 000 00.000 000.00 Completed Startup
1. Early Stage VC 31-Mar-2015 $4.75M $4.75M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Urotronic Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A3 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A2 0,000,000 00.000000 00 00 00 00 00.000
Series A1 3,000,000 $0.000100 $0.33 $0.33 1x $0.33 23.08%
To view this company’s complete Cap Table, request access »

Urotronic Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NxThera Formerly VC-backed Maple Grove, MN 00 000.00 000000&0 000.00
00000000 0000000 Corporate Backed or Acquired Wixom, MI 000 00000 000000000 00000
00000000 Formerly VC-backed Pleasanton, CA 000 00000 000000&0 00000
000000 0000000 Venture Capital-Backed San Jose, CA 000 00000 00000000000 00000
000 0000000 Venture Capital-Backed Rosh Ha'ayin, Israel 0000 0000000000 0000
To view this company’s complete list of competitors, request access »

Urotronic Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
CDBI Partners Venture Capital Minority 000 0000 000000 0
HM Ventures Venture Capital Minority 000 0000 000000 0
Legend Capital Venture Capital Minority 000 0000 000000 0
Ocxprouro Other Minority 000 0000 000000 0
HGInnovation Ventures Other Minority 000 0000 000000 0

Urotronic Executive Team (1)

Name Title Board
Seat
Contact
Info
David Perry Chief Executive Officer & Board Member

Urotronic Board Members (7)

Name Representing Role Since Contact
Info
Ching Tan Self Board Member 000 0000
David Perry Urotronic Chief Executive Officer & Board Member 000 0000
Douglas Kohrs Self Board Member 000 0000
Hui Hu Ph.D Self Co-Founder & Board Member 000 0000
Junfeng Wang Legend Capital Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »